These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35632556)

  • 21. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis.
    García-Azorín D; Do TP; Gantenbein AR; Hansen JM; Souza MNP; Obermann M; Pohl H; Schankin CJ; Schytz HW; Sinclair A; Schoonman GG; Kristoffersen ES
    J Headache Pain; 2021 Sep; 22(1):108. PubMed ID: 34535076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
    Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England.
    Andrews NJ; Stowe J; Ramsay ME; Miller E
    Lancet Reg Health Eur; 2022 Feb; 13():100260. PubMed ID: 34927118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases.
    Taquet M; Husain M; Geddes JR; Luciano S; Harrison PJ
    EClinicalMedicine; 2021 Sep; 39():101061. PubMed ID: 34368663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273).
    Préta LH; Contejean A; Salvo F; Treluyer JM; Charlier C; Chouchana L
    Br J Clin Pharmacol; 2022 Jul; 88(7):3529-3534. PubMed ID: 35174524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombotic events following the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) in Aotearoa New Zealand: A self-controlled case series study.
    Walton M; Tomkies R; Teunissen T; Lumley T; Hanlon T
    Thromb Res; 2023 Feb; 222():102-108. PubMed ID: 36634464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis.
    Adjaï F; Fournier D; Dolladille C; Lebrun-Vignes B; Bihan K
    Therapie; 2024 Mar; ():. PubMed ID: 38584049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
    Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
    Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
    Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
    J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
    Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
    Front Immunol; 2022; 13():975363. PubMed ID: 36119092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
    Ferner RE; Stevens RJ; Anton C; Aronson JK
    Drug Saf; 2022 Feb; 45(2):137-144. PubMed ID: 35064899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients.
    Lim SY; Yoon YI; Kim JY; Tak E; Song GW; Kim SH; Lee SG
    Immune Netw; 2022 Jun; 22(3):e24. PubMed ID: 35799703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study.
    Göbel CH; Heinze A; Karstedt S; Morscheck M; Tashiro L; Cirkel A; Hamid Q; Halwani R; Temsah MH; Ziemann M; Görg S; Münte T; Göbel H
    Pain Ther; 2021 Dec; 10(2):1309-1330. PubMed ID: 34313952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.